iShares U.S. Pharmaceuticals ETF
IHE
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- iShares U.S. Pharmaceuticals ETF (IHE), sponsored and managed by BlackRock, Inc., seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index, a free float-adjusted, market capitalization-weighted index composed of U.S. equities in the pharmaceuticals industry. The ETF provides passive exposure to a diversified portfolio of approximately 40 pharmaceutical companies, with top holdings including Eli Lilly and Company (LLY; approximately 20-25% weight), Johnson & Johnson (JNJ; approximately 22-24% weight), Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), Bristol-Myers Squibb Company (BMY), and others such as Viatris Inc. (VTRS), Royalty Pharma plc (RPRX), Zoetis Inc. (ZTS), and Elanco Animal Health Inc. (ELAN); the index caps individual company weights at 22.5% and rebalances quarterly. Launched on May 1, 2006, and listed on NYSE Arca, IHE has grown to manage approximately $585 million in assets under management as of late 2025, with an expense ratio of 0.38-0.39% and quarterly dividend distributions yielding around 1.65%. It targets institutional and retail investors seeking sector-specific exposure within the healthcare industry, primarily to U.S. markets, through a sampling strategy that replicates the index's profile. In recent developments, BlackRock, the ETF's issuer, completed the acquisition of HPS Investment Partners in June 2025, enhancing its capabilities across public and private credit markets and integrating with its $3 trillion fixed income franchise to better serve client demands in evolving financial landscapes. The firm also expanded collaborations, including the December 2025 launch of the iShares Quantum Computing UCITS ETF tracking a STOXX index, signaling ongoing innovation in thematic ETF offerings. No specific product updates, splits, or index reconstitutions for IHE were announced in 2024-2025, though the fund maintains steady quarterly rebalancing amid stable AUM growth and performance tracking closely to its benchmark. Headquartered in New York, BlackRock oversees IHE as part of its iShares ETF platform, with no direct subsidiaries or parent relationships altering the fund's structure.